Logo

American Heart Association

  1
  0


Final ID: WP139

Telestroke service for Endovascular Stroke Treatment in Canada: Results from the OPTIMISE Registry

Abstract Body: Background: Telestroke allows rapid assessment of patients presenting with acute stroke symptoms for intravenous thrombolysis or endovascular thrombectomy (EVT). Although the safety and efficacy of telestroke services for the delivery of intravenous thrombolysis has been well established, evidence on EVT decision-making is scarce.
Methods: We analysed data from OPTIMISE, a quality improvement registry to support EVT implementation in Canada. We assessed for unadjusted differences in baseline characteristics, time metrics, and procedural outcomes between patients transferred for EVT who received telestroke consultation and those who didn’t receive the service. We used mixed-effects logistic regression models to compare the likelihood for symptomatic intracerebral hemorrhage (SICH), good functional outcome (defined as a modified Ranking Scale score of 0-2), or all-cause mortality at 90 days between the two groups. All models were adjusted for predefined confounders and participating centre.
Results: Patients receiving telestroke consultation (n=997; 15%) had higher rates of carotid terminus occlusion (23.9% vs. 14.3%), but similar rates of M1-MCA and basilar occlusion compared to patients not receiving telestroke consultation (n=5,561). Patients receiving telestroke consultation had longer onset-to-door time (300.5 vs. 175 minutes) and onset-to-groin puncture time (344 vs. 233 minutes), but shorter door-to-groin puncture time (40 vs.70 minutes) compared to those not receiving telestroke consultation. No differences in groin puncture to reperfusion times, successful reperfusion rates, or adverse periprocedural events were found between the two groups. In the unadjusted analyses patients receiving telestroke consultation had higher rate of SICH (6.5% vs 3.1%), a lower rate for good functional outcome at 90-days (35.6% vs. 40.6%) and higher rate for all-cause mortality at 90 days (39.9% vs. 27.5%) compared to those not receiving telestroke consultation. Those differences were eliminated in the adjusted analyses.
Conclusion: Patients receiving telestroke consultation prior to EVT have prolonged treatment times and worse outcomes, compared to patients that did not receive telestroke consultation prior to EVT. The higher risk for unfavorable outcomes was eliminated after adjustment for confounders, including treatment time. There is a need for quality improvement initiatives to optimize the workflow of patients receiving telestroke consultation prior to EVT.
  • Tarek, Mohamed  ( McMaster University/Population Health Research Institute , Hamilton , Ontario , Canada )
  • Catanese, Luciana  ( McMaster University/Population Health Research Institute , Hamilton , Ontario , Canada )
  • Mandzia, Jennifer  ( UNIVERSITY OF WESTERN ONTARIO , London , Ontario , Canada )
  • Shankar, Jai  ( University of manitoba , Winnipeg , Manitoba , Canada )
  • Tkach, Aleksander  ( Kelowna General Hospital , Kelowna , British Columbia , Canada )
  • Shoamanesh, Ashkan  ( MCMASTER UNIVERSITY , Hamilton , Ontario , Canada )
  • Sharma, Mukul  ( McMaster University PHRI , Hamilton , Ontario , Canada )
  • Stotts, Grant  ( The Ottawa Hospital , Ottawa , Ontario , Canada )
  • Katsanos, Aristeidis  ( McMaster University , Hamilton , Ontario , Canada )
  • Author Disclosures:
    Mohamed Tarek: DO NOT have relevant financial relationships | Luciana Catanese: No Answer | Jennifer Mandzia: No Answer | Jai Shankar: DO have relevant financial relationships ; Research Funding (PI or named investigator):Medtronic Canada:Active (exists now) | Aleksander Tkach: DO NOT have relevant financial relationships | Ashkan Shoamanesh: DO have relevant financial relationships ; Consultant:AstraZeneca:Active (exists now) ; Research Funding (PI or named investigator):Daiichi Sankyo:Active (exists now) ; Consultant:Bioxides:Past (completed) ; Speaker:Bayer AG:Active (exists now) ; Speaker:Daiichi Sankyo:Active (exists now) ; Speaker:AstraZeneca:Active (exists now) ; Consultant:Bayer AG:Active (exists now) ; Consultant:Daiichi Sankyo:Active (exists now) | Mukul Sharma: DO have relevant financial relationships ; Research Funding (PI or named investigator):Bayer:Active (exists now) ; Research Funding (PI or named investigator):Daiichi Sakyo:Active (exists now) ; Research Funding (PI or named investigator):Portola:Past (completed) ; Research Funding (PI or named investigator):Alexion:Past (completed) ; Consultant:Bayer:Active (exists now) ; Research Funding (PI or named investigator):Astra Zeneca:Active (exists now) ; Research Funding (PI or named investigator):Janssen:Past (completed) ; Research Funding (PI or named investigator):BMS:Past (completed) | Grant Stotts: DO NOT have relevant financial relationships | Aristeidis Katsanos: DO NOT have relevant financial relationships
Meeting Info:
Session Info:

Health Services, Quality Improvement, and Patient-Centered Outcomes Posters I

Wednesday, 02/05/2025 , 07:00PM - 07:30PM

Poster Abstract Session

More abstracts on this topic:
A Case Series of Papillary Fibroelastomas on the Coumadin ridge

Aboukhatwa Omar, Akiki Elias, Kurmann Reto, Larson Kathryn, Keeney Michael, Bois Melanie, Klarich Kyle

10-Year Trend Analysis of Medicare Payment in Stroke Inpatient Hospital Admission

Wong Ka-ho, Krothapalli Neeharika, Littig Lauren, Champagne Alison, Majersik Jennifer, Reddy Vivek, De Havenon Adam

More abstracts from these authors:
Outcomes of acute ischemic stroke patients in primary stroke centers versus comprehensive stroke centers: a pre-specified analysis of the Alteplase compared to Tenecteplase trial

Gutierrez Diego, Hunter Gary, Ademola Ayoola, Dowlatshahi Dar, Swartz Richard, Catanese Luciana, Buck Brian, Ganesh Aravind, Sajobi Tolulope, Menon Bijoy, Almekhlafi Mohammed, Ignacio Katrina, Singh Nishita, Tkach Aleksander, Manosalva Alzate Herbert, Bala Fouzi, Horn Mackenzie, Khosravani Houman, Shankar Jai, Tarek Mohamed

Restarting anticoagulation in FXa inhibitor associated intracerebral hemorrhage treated with andexanet reduces thrombotic events

Sharma Mukul, Eikelboom John, Xu Lizhen, Bamberg Krister, Falkenberg Cecilia, Ladenvall Per, Penland Robert, Narayan Rohit, Shoamanesh Ashkan

You have to be authorized to contact abstract author. Please, Login
Not Available

Readers' Comments

We encourage you to enter the discussion by posting your comments and questions below.

Presenters will be notified of your post so that they can respond as appropriate.

This discussion platform is provided to foster engagement, and simulate conversation and knowledge sharing.

 

You have to be authorized to post a comment. Please, Login or Signup.


   Rate this abstract  (Maximum characters: 500)